IO Biotech, Inc. (IOBTQ)
OTCMKTS · Delayed Price · Currency is USD
0.0020
+0.0019 (1,900.00%)
At close: Aug 10, 2026
IO Biotech Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 30.66 | 60.03 | 143.19 | 142.59 | 211.53 | 3.41 |
Cash & Short-Term Investments | 30.66 | 60.03 | 143.19 | 142.59 | 211.53 | 3.41 |
Cash Growth | -61.76% | -58.08% | 0.42% | -32.59% | 6112.36% | - |
Other Current Assets | 6.17 | 4.92 | 4.06 | 5.63 | 10.21 | 2.23 |
Total Current Assets | 36.83 | 64.95 | 147.26 | 148.22 | 221.74 | 5.64 |
Net Property, Plant & Equipment | 1.85 | 2.36 | 3.11 | 3.23 | 0.16 | - |
Other Long-Term Assets | 1.28 | 0.39 | 0.36 | 0.35 | 0.4 | 0.02 |
Total Assets | 39.96 | 67.7 | 150.72 | 151.81 | 222.29 | 5.65 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Accounts Payable | 5.59 | 4.66 | 3.88 | 4 | 3.93 | 0.52 |
Accrued Expenses | 11.94 | 14.11 | 11.18 | 6.16 | 6.38 | 2.53 |
Current Portion of Leases | 0.79 | 0.72 | 0.66 | 0.52 | - | - |
Total Current Liabilities | 18.31 | 19.49 | 15.72 | 10.68 | 10.31 | 3.05 |
Long-Term Debt | 16.66 | - | - | - | - | - |
Long-Term Leases | 0.67 | 1.2 | 1.84 | 2.28 | - | - |
Other Long-Term Liabilities | 3.4 | - | - | - | 0.06 | - |
Total Long-Term Liabilities | 20.73 | 1.2 | 1.84 | 2.28 | 0.06 | - |
Total Liabilities | 39.05 | 20.68 | 17.56 | 12.95 | 10.36 | 3.05 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Common Stock | 0.07 | 0.07 | 0.07 | 0.03 | 0.03 | 0.03 |
Additional Paid-in Capital | 424.34 | 413.11 | 406.59 | 326.71 | 319.67 | 1.11 |
Accumulated Other Comprehensive Income | -7.17 | -6.85 | -9.67 | -10.14 | -1.49 | 1.96 |
Retained Earnings | -416.33 | -359.31 | -263.82 | -177.74 | -106.28 | -38.4 |
Shareholders' Equity | 0.91 | 47.02 | 133.16 | 138.85 | 211.92 | -35.3 |
Total Liabilities & Equity | 39.96 | 67.7 | 150.72 | 151.81 | 222.29 | 5.65 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Total Debt | 18.12 | 1.92 | 2.49 | 2.79 | 0 | 0 |
Net Cash (Debt) | 12.55 | 58.12 | 140.7 | 139.8 | 211.53 | 3.41 |
Net Cash Growth | -83.95% | -58.70% | 0.64% | -33.91% | 6112.36% | - |
Net Cash Per Share | 0.19 | 0.88 | 3.23 | 4.85 | 48.79 | 19.22 |
Book Value | 0.91 | 47.02 | 133.16 | 138.85 | 211.92 | -35.3 |
Book Value Per Share | 0.01 | 0.71 | 3.06 | 4.82 | 48.88 | -199.23 |
Tangible Book Value | 0.91 | 47.02 | 133.16 | 138.85 | 211.92 | -35.3 |
Tangible Book Value Per Share | 0.01 | 0.71 | 3.06 | 4.82 | 48.88 | -199.23 |